Metaraminol

• Adrenergic Agents
• Adrenergic alpha-Agonists
• Sympathomimetics
• Vasoconstrictor Agents
• ATC:C01CA09

• Aramine
• Hydroxynorephedrine
• Icoral B
• L-Metaraminol
• M-Hydroxy Norephedrine
• M-Hydroxyphenylpropanolamine
• M-Hydroxypropadrine
• Metaradrine
• Metaraminol Bitartrate
• Metaraminolum [Inn-Latin]
• Metaraminolum [Latin]
• Pressonex
• Pressorol

• No information avaliable

C₉H₁₃NO₂

http://www.rxlist.com/cgi/generic2/metar.htm

Metaraminol MSDS

Brit. pat. 353,361 (1930 to I. G. Farben); Brit. pat. 396,951 (1932 to I. G. Farben); Swiss pat. 162,267 (1931 to I. G. Farben); U.S. pats. 1,948,162 ans 1,951,302; Hartung, U.S. pat. 1,995,709 (1935 to Sharp & Dohme)

167.205 g/mol

107.5 ^oC

1000 g/L

Solid

0.6

Intramuscular injection; Intravenous injection

For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage

Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol acts on both α1-adrenergic receptors but appears to have no effect on β-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels.

The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection.

LD₅₀=240 mg/kg (rat, oral); LD₅₀=99 mg/kg (mouse, oral)

Humans and other mammals